Second, because the P+L combination can also work in BRAF V600E-mutated cancers, starting with L+P is an option if time is required for molecular profiling, especially considering that the growth of ATC is extremely rapid and that the possible clinical benefit can also be quite rapid. The gene discussed is BRAF; the disease is cancer.